Daniel A. Boehnen

Daniel A. Boehnen is a founding partner at McDonnell Boehnen Hulbert & Berghoff LLP (MBHB), where his practice primarily focuses on trials, appeals, opposition proceedings, and various disputed patent matters. Although his firm's broader practice encompasses a wide range of high-tech industries including biotechnology & pharmaceuticals, chemical, electrical, mechanical, medical devices, networking, and software, his tracked patent litigation experience points to a particular emphasis on pharmaceutical patent disputes.

Based on available case data, Mr. Boehnen predominantly represents plaintiffs in patent litigation. He has served as lead counsel for Veloxis Pharmaceuticals Inc. in two significant Abbreviated New Drug Application (ANDA) patent infringement cases concerning extended-release tacrolimus formulations, an immunosuppressant. These cases include Veloxis Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Ltd. and Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al.

In Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al., Veloxis secured a consent judgment and permanent injunction in January 2024, blocking Accord Healthcare and Intas Pharmaceuticals from commercializing a generic version of ENVARSUS XR® tacrolimus under ANDA No. 217255 until patent expiry. Similarly, in Veloxis Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Ltd., a deal was reached blocking a proposed generic version of Envarsus XR until May 2028, resulting in a consent judgment resolving patent claims.

Mr. Boehnen's practice also includes opposition proceedings, aligning with his firm's demonstrated expertise in Patent Trial and Appeal Board (PTAB) and Inter Partes Review (IPR) proceedings. He earned his J.D. from Cornell Law School in 1976 and holds a B.S. in Chemical Engineering from the University of Notre Dame. He is admitted to practice in Illinois and before the U.S. Patent & Trademark Office, with additional admissions to several U.S. Courts of Appeals and District Courts, including the U.S. Court of Appeals for the Federal Circuit and the Supreme Court of the United States.